Medpace Holdings

MEDP · NASDAQ

$622.43+$2.77 (+0.45%)TodayMarket closed ·
Prev close $619.66

About MEDP

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company is headquartered in Cincinnati, Ohio and currently employs 6,300 full-time employees. The company went IPO on 2016-08-11. The firm partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The firm also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.

Employees
6,300
Headquarters
Cincinnati, Ohio
Listed
Aug 11, 2016
Sector
Health Care
Industry
Life Sciences Tools & Services

MEDP key statistics

Market cap
17.30B
Price-earnings ratio
36.39
Dividend yield
—
Average volume
257.89K
Volume
241.84K
Open price
$626.64
High today
$637.15
Low today
$613.13
52 Week high
$677.90
52 Week low
$373.00

Medpace Holdings (MEDP) at a glance

As of Oct 20, 2026, Medpace Holdings (MEDP) shares are priced at $622.43, giving the company a market cap of 17.30B and a price-to-earnings ratio of 36.39.

Today the stock has traded between $613.13 and $637.15. The current price is 1.5% above the day's low and 2.3% below its high.

Volume so far is 241.84K shares, in line with the average of 257.89K shares a day.

Over the past year Medpace Holdings has ranged from $373.00 to $677.90, and now sits 82% of the way up that range.

Medpace Holdings met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $4.25 per share against an estimate of $4.05.

The average analyst price target is $602.33, 3.2% below the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

20%of 10 analyst ratings say Buy
  • Buy20.0%
  • Hold80.0%
  • Sell0.0%
Price target · 15 analystsAvg $602.33
Low
$381.59
Now
$622.43
High
$726.60

MEDP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 9.8% on average.

  1. Q3 FY24: reported $3.01 per share against an estimate of $2.83
  2. Q4 FY24: reported $3.67 per share against an estimate of $3.02
  3. Q1 FY25: reported $3.67 per share against an estimate of $3.11
  4. Q2 FY25: reported $3.10 per share against an estimate of $3.02
  5. Q3 FY25: reported $3.86 per share against an estimate of $3.59
  6. Q4 FY25: reported $4.67 per share against an estimate of $4.26
  7. Q1 FY26: reported $4.28 per share against an estimate of $3.96
  8. Q2 FY26: reported $4.25 per share against an estimate of $4.05

MEDP news

  • Piero Cingari

    Earnings Volatility Watch: Bloom Energy and Other 11 Stocks Are Priced For Double-Digit Swings

  • Press releaseBusiness Wire

    Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026

  • Press releasePRNewswire

    Kuehn Law Encourages Investors of Medpace Holdings, Inc. to Contact Law Firm

  • Vandana Singh

    Medpace Soars After Q2 Beat, Strong Backlog Fuels Higher 2026 Outlook

  • Piero Cingari

    Brent Tops $100, Alphabet, Tesla Sink Nasdaq 100: Stock Market Today

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

Similar companies

Companies in the same industry as Medpace Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.